potassium canrenoate + spironolactone

Potassium canrenoate + spironolactone refers to a specific pharmacological regimen evaluated in the ALBATROSS clinical trial, sponsored by Assistance Publique - Hôpitaux de Paris. This regimen consists of an initial 200 mg intravenous bolus of potassium canrenoate (a water-soluble aldosterone antagonist prodrug) followed by a maintenance dose of 25 mg oral spironolactone daily. Both agents function as mineralocorticoid receptor antagonists (MRAs), which compete with aldosterone for binding sites in the heart and kidneys to mitigate the adverse effects of mineralocorticoid overactivation, such as fibrosis and electrolyte imbalance. The ALBATROSS trial specifically investigated the efficacy of early aldosterone blockade initiated within 72 hours of an acute myocardial infarction to improve six-month cardiovascular outcomes, although the study did not demonstrate a significant benefit in the overall population of patients without heart failure.

Brand names

AldactoneSoludactone

Other names

spironolactonepotassium canrenoateALBATROSS trial regimenearly aldosterone blockade